CirculoGene provides blood-based testing for detecting clinically significant tumor DNA/RNA alterations. The company uses a patented methodology for DNA yield and RNA preservation, employing next-generation sequencing and polymerase chain reaction instrumentation for DNA and RNA detection.

CirculoGene

Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One tube, one week, complete results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + MSI + PD-L1. 

CONTACT
info@circulogene.com

For Asia Pacific inquiries,
please email AsiaPacfic@circulogene.com

For Middle Eastern inquiries,
please email Irem.Agin@circulogene.com.tr

CIRCULOGENE

Tumor markers play a crucial role in the diagnosis and management of cancer. At Circulogene, our TumorClear test uses next-generation sequencing to provide a detailed molecular profile of your tumor, including essential guideline and expert-recommended DNA mutations. This comprehensive analysis helps your physician tailor a treatment plan that is specifically designed for your unique cancer. Learn more about the significance of tumor markers and how they can influence your treatment at https://lnkd.in/exce_3h9

At Circulogene, we harness the power of advanced diagnostics technology to revolutionize healthcare. Our proprietary methodologies, including next-generation sequencing (NGS) and polymerase chain reaction (PCR), allow us to provide comprehensive and precise diagnostic results. By utilizing these state-of-the-art techniques, we offer unparalleled accuracy in detecting tumor DNA and RNA, enabling personalized treatment plans for our patients. Discover more about how we are leading the way in medical innovation at https://lnkd.in/exce_3h9

I recently heard from a friend that his parent had been diagnosed with stage 4 cancer. We are very lucky to live at a time when there are exceptional diagnostic tools, procedural tools, doctors/staff, treatment options and facilities available to treat patients with stage 4 cancer, improving outcomes and life expectancy.
Several years ago, when my father was battling his cancer, he would tell me he was going to win and beat this! We cheered him on as he fought the good fight and I knew it made a difference for him that we were all fighting at his side. It wasn’t enough, he lived for a year and 2 weeks after his diagnosis. As you might expect, i think about him often and wonder if he had current opinions available to him, would he still be alive?
There are many warriors out there who have a much better chance at winning today than my father did because there are many more weapons to use. I work in the cancer diagnostic industry and have met many exceptional people who are fighting cancer as physicians, nurses, program directors, and industry leaders. We are all working to provide the best options for each individual. 
I was missing my dad today and hoping my friend and his family can win. Im cheering for them as well.

#findacure
#cancersucks
#warriorlife

Why Circulogene? Complete, Accurate, and Timely Testing.

Dr. Walker is one of the most trusted professionals in the industry. Hear as he walks us thorugh the importance of liquid biposy testing for early detection.

Hear from Mike Mullen our founder, on "Why Circulogene".

msh id	COM:CIRCULOGENE
symbol	-
name	CirculoGene
homepage url	https://circulogene.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology and Medical Diagnostics
market	PRIVATE
employee count	38
crunchbase url	-
linkedin url	https://www.linkedin.com/company/circulogene-diagnostics
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

CIRC

COM:CIRCULOGENE

CirculoGene

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-